The impact of sanction and healthcare system reform on the healthcare performance and pharmaceutical market in Iran; 2001-2016

References

• Heshmati B, Joulaei H. Iran’s health-care system in transition. Lancet. 2016;387(10013):29–30.
   PubMed Web of Science ®Google Scholar
• Zahra Ebrahim AAN. A review on the country health system, its challenges and the corrective solutions. Mod Appl Sci. 2016;10(6):227–237.
   Google Scholar
• Shadpour K. Health sector reform in Islamic Republic of Iran. Hakim Res J. 2006;9(3):1–18
   Google Scholar
• Takian A, Doshmangir L, Rashidian A. Implementing family physician programme in rural Iran: exploring the role of an existing primary health care network. Fam Pract. 2013;30(5):551–559.
   PubMed Web of Science ®Google Scholar
• Ibrahimipour H, Maleki M-R, Brown R, Gohari M, Karimi I, Dehnavieh R. A qualitative study of the difficulties in reaching sustainable universal health insurance coverage in Iran. Health Policy Plan. 2011;26(6):485–4952130387910.1093/heapol/czq084
   PubMed Web of Science ®Google Scholar
• Pourasghari H, Jafari M, Bakhtiari M, Keliddar I, Irani A, Afshari M. Analysis of equality in Iranian household healthcare payments during Iran’s fourth development program. Electron Physician. 2016;8(7):2645.
   PubMedGoogle Scholar
• Reich MR. The politics of health sector reform in developing countries: three cases of pharmaceutical policy. Health Policy. 1995;32(1-3):47–77.
   PubMed Web of Science ®Google Scholar
• Hajizadeh M, Connelly LB. Equity of health care financing in Iran: the effect of extending health insurance to the uninsured. Oxf Dev Stud. 2010;38(4):461–476.
   Google Scholar
• Moradi-Lakeh M, Vosoogh-Moghaddam A. Health sector evolution plan in Iran; equity and sustainability concerns. Int J Health Policy Manag. 2015;4(10):637.
   PubMed Web of Science ®Google Scholar
• Kebriaeezadeh A, Koopaei NN, Abdollahiasl A, Nikfar S, Mohamadi N. Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries. DARU. 2013;21(1):52.
   PubMedGoogle Scholar
• Afsoon A, Mehdi RY, Hamed Z, Asghar HA. Catastrophic health expenditures in Iran: a review of the literature. Payesh J Iran Inst Health Sci Res. 1:7–17.
   Google Scholar
• Mossialos E, Oliver A. An overview of pharmaceutical policy in four countries: France, Germany, the Netherlands and the United Kingdom. Int J Health Plann Manag. 2005;20(4):291–306.
   PubMed Web of Science ®Google Scholar
• Cheraghali AM. Iran pharmaceutical market. Iran J Pharm Res. 2010;1:1–7
   Google Scholar
• Cheraghali AM. Impacts of international sanctions on Iranian pharmaceutical market. DARU. 2013;21(1):64.
   PubMedGoogle Scholar
• Jakovljevic MB, Djordjevic N, Jurisevic M, Jankovic S. Evolution of the Serbian pharmaceutical market alongside socioeconomic transition. Expert Rev Pharmacoecon Outcomes Res. 2015;15(3):521–530.
   PubMed Web of Science ®Google Scholar
• Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics. 2003;21(2):89–103.
   PubMed Web of Science ®Google Scholar
• Rusu A, Kuokkanen K, Heier A. Current trends in the pharmaceutical industry–a case study approach. Eur J Pharm Sci. 2011;44(3):437–440.
   PubMed Web of Science ®Google Scholar
• Shabaninejad H, Mehralian G, Rashidian A, Baratimarnani A, Rasekh HR. Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market. DARU. 2014;22(1):35.
   PubMedGoogle Scholar
• Cheraghali A, Nikfar S, Behmanesh Y, Rahimi V, Habibipour F, Tirdad R, et al. Evaluation of availability, accessibility and prescribing pattern of medicines in the Islamic Republic of Iran. 2004.
   Google Scholar
• Aliakbari Saba Roshanak SM. Health care services is called utilization in Iran: AMAR Statistics Center of Iran; 2016. p. 9–14. In Persian.
   Google Scholar
• Maryam K. National health accounts; 2001-2010: AMAR Statistics Center of Iran; 2015. p. 33–4.
   Google Scholar
• Farhadi Jamaleddin FA. National health accounts; 2001-2013: AMAR Statistics Center of Iran; 2016. p. 9–13.
   Google Scholar
• Kaplan W, Laing R. Local production of pharmaceuticals: industrial policy and access to medicines, an overview of key concepts, issues and opportunities for future research; 2005.
   Google Scholar
• Dinarvand R. New national drug policy in Iran leading to expanded pharmaceutical market and extended access of public to medicines; 2009.
   Google Scholar
• Mehrdad R. Health system in Iran. JMAJ. 2009;52(1):69–73
   Google Scholar
• Asadi-Lari M, Sayyari A, Akbari M, Gray D. Public health improvement in Iran—lessons from the last 20 years. Public Health. 2004;118(6):395–402.
   PubMed Web of Science ®Google Scholar
• Maharlouei N, Akbari M, Akbari M, Lankarani KB. Socioeconomic status and satisfaction with public healthcare system in Iran. Int J Community Based Nurs Midwifery. 2017;5(1):22
   PubMedGoogle Scholar
• Davari M, Walley T, Haycox A. Pharmaceutical policy and market in Iran: past experiences and future challenges. J Pharm Health Serv Res. 2011;2(1):47–52.
   Google Scholar
• Van Boeckel TP, Gandra S, Ashok A, Caudron Q, Grenfell BT, Levin SA, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis. 2014;14(8):742–750.
   PubMed Web of Science ®Google Scholar
• Mohammadtaheri Z, Pourpaki M, Mohammadi F, Namdar R, Masjedi M-R. Surveillance of antimicrobial susceptibility among bacterial isolates from intensive care unit patients of a tertiary-care university hospital in Iran: 2006–2009. Chemotherapy. 2010;56(6):478–484.
   PubMed Web of Science ®Google Scholar
• Mehralian G, Rajabzadeh A, Reza Sadeh M, Reza RH. Intellectual capital and corporate performance in Iranian pharmaceutical industry. J Intellect Cap. 2012;13(1):138–158.
   Google Scholar
• Dadfar H, Dahlgaard JJ, Brege S, Alamirhoor A. Linkage between organisational innovation capability, product platform development and performance: the case of pharmaceutical small and medium enterprises in Iran. Total Qual Manag Bus Excell. 2013;24(7-8):819–834.
   Web of Science ®Google Scholar
• Davari M, Haycox A, Walley T. Health care financing in iran; is privatization a good solution? Iran J Public Health. 2012;41(7):14.
   PubMed Web of Science ®Google Scholar
• Azizi S, Ghytasivand F, Fakharmanesh S. Impact of brand orientation, internal marketing and job satisfaction on the internal brand equity: the case of Iranian’s food and pharmaceutical companies. Int Rev Manag Mark. 2012;2(2):122–129
   Google Scholar
• Taher A, Stuart EW, Hegazy I. The pharmacist’s role in the Egyptian pharmaceutical market. Int J Pharm Healthc Mark. 2012;6(2):140–155.
   Google Scholar
• Kaplan WA, Wirtz VJ, Stephens P. The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysis. PLoS One. 2013;8(9):e74399.
   PubMed Web of Science ®Google Scholar
• Imanieh MH, Sadati AK, Moghadami M, Hemmati A. Introducing the Urban Community Health Center (UCHC) as a nascent local model: will it be a linchpin in the health sector reform in Iran? Int J Health Policy Manag. 2015;4(5):331.
   PubMedGoogle Scholar